Drugmaker Shire delivers earnings beat amid deal-making push

By Paul Sandle LONDON (Reuters) - Drugmaker Shire reported better-than-expected profit in the last quarter of 2015, a period when management could have been distracted by buying rare disease specialist Dyax and the final stages of its $32 billion pursuit of Baxalta International. Chief Executive Flemming Ornskov said 2015 started and ended with two important deals in rare diseases -- NPS Pharma and Dyax -- before he secured the transformative merger with Baxalta last month. Baxalta, which makes